Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
History
Social responsibility
Our companies
Debiopharm Group
Debiopharm S.A.
Debio R.P. S.A.
Debioclinic S.A.
Debiovision Inc.
Debioinnovation S.A.
Business Model
Strengths
Development capabilites
Preclinical
Clinical
Manufacturing
Regulatory
Innovative drug delivery and formulation
Partnering
Licensing-in
Licensing-out
Partners
Pipeline
Commercial Products
Eloxatin®
Decapeptyl®
News & Events
Press Releases
Awards
Publications
Conferences
News
02.09.2008
Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment
21.08.2008
Doctor Manel Esteller Receives the Debiopharm Life Sciences Award For his Outstanding Research in Epigenetic Oncology
Home
News & Events
Press Releases
PRESS RELEASES
Order
Date asc
Date desc
Title asc
Title desc
Ordering
Display #
5
10
15
20
25
30
50
Date
Item Title
15-May-2008
Debiopharm Signs License Agreement for Marketing of Salvacyl®/Moapar 3-month for Sexual Deviations
23-May-2007
Salvacyl®/ Maopar® 3-month obtains european mutual recognition to treat sexual deviations
19-Jun-2006
Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men
< Prev
1
Next >
Results 1 - 3 of 3
Triptorelin – Trelstar® – Decapeptyl® - Pamorelin®
( 8 items )
Debio 8609 Sanvar®
( 12 items )
Debio 025
( 5 items )
Debio 9902 - ZT-1
( 8 items )
Debio 0614 (istaroxime)
( 2 items )
Debio 0507
( 3 items )
Debio 0719
( 1 items )
Debio 0824
( 1 items )
Debio 0617
( 1 items )
Oxaliplatin – Eloxatin® – Elplat®
( 10 items )
Other News
( 45 items )
